# Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

> **NCT04504526** · EARLY_PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital of Fujian Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma
- Multiple Myeloma
- Leukemia

## Interventions

- **DRUG:** 68Ga-Pentixafor

## Key facts

- **NCT ID:** NCT04504526
- **Lead sponsor:** First Affiliated Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-07
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504526, "Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04504526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*